Table 5.

Treatment emergent adverse events for all causalities (single dose)

System organ class	Number of subjects (%) with adverse events [number of adverse events]
	Placebo			Dose of selisistat
	Male (fasted) (n = 12)	Male (fed) (n = 2)	Female (fasted) (n = 2)	Male 5 mg (fasted) (n = 6)	Male 25 mg (fasted) (n = 6)	Male 75 mg (fasted) (n = 6)	Male 150 mg (fasted) (n = 6)	Male 150 mg (fed) (n = 6)	Male 300 mg (fasted) (n = 6)	Female 300 mg (fasted) (n = 6)	600 mg (fasted) (n=6)
Nervous system disorders
Headache	2 (17%) [2]		1 (50%) [1]	1 (17%) [1]		1 (17%) [1]	2 (33%) [2]	1 (17%) [1]		5 (83%) [5]	1 (17%) [1]
Dizziness						1 (17%) [1]
Dizziness postural						1 (17%) [1]
Somnolence								1 (17%) [1]
Syncope							1 (17%) [1]
Total	2 (17%) [2]		1 (50%) [1]	1 (17%) [1]		2 (33%) [3]	2 (33%) [3]	1 (17%) [2]		5 (83%) [5]	1 (17%) [1]
Musculoskeletal and connective tissue disorders
Pain in extremity	1 (8%) [1]		1 (50%) [1]							1 (17%) [1]
Arthralgia							1 (17%) [1]
Total	1 (8%) [1]		1 (50%) [1]				1 (17%) [1]			1 (17%) [1]
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain	1 (8%) [1]							1 (17%) [1]
Total	1 (8%) [1]							1 (17%) [1]
Skin and subcutaneous disorders
Dermatitis Acneiform	1 (8%) [1]
Rash							1 (17%) [1]
Total	1 (8%) [1]						1 (17%) [1]
Cardiac disorders
Palpitations						1 (17%) [1]
Total						1 (17%) [1]
General disorders and administration site conditions
Fatigue						1 (17%) [1]
Total						1 (17%) [1]
Infections and infestations
Nasopharyngitis								1 (17%) [1]
Total								1 (17%) [1]
Gastrointestinal disorders
Nausea										1 (17%) [1]
Total										1 (17%) [1]
Overall total	5 (42%) [5]	0 (0%) [0]	1 (50%) [1]	1 (17%) [1]	0 (0%) [0]	2 (33%) [5]	3 (50%) [5]	2 (33%) [4]	0 (0%) [0]	5 (83%) [7]	1 (17%) [1]

n = number of subjects studied.